Answers are grounded in this paper and cite their sources.
Clinical evaluation of glasmacinal reports tolerability and pharmacokinetic interactions in drug evaluations, suggesting low risk of adverse interactions.
Glasmacinal was well tolerated in single doses up to 750 mg and repeat doses up to 375 mg. Glasmacinal may be a victim of selected drugs that impact CYP3A4 and/or P-gp but is unlikely to be a perpetrator of clinically relevant DDIs.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: